Type 1 Diabetes Research

A Step Into Freedom From T1DM

About Me

Hello

I amShivani Desai

Type 1 diabetes researcher and enthusiast

Welcome to T1DM.org! It is a platform which consolidates my work about type 1 diabetes (T1DM) and its management. This forum invites an open interaction from national and international experts to manage type 1 diabetes, share their knowledge and collaborate to work towards freedom from this painful disease.

This forum includes the papers published by the author in the journals of repute. These papers primarily involve the content related to the etiology and pathophysiology of T1DM, the application of mesenchymal stem cells to manage T1DM and improve the quality of life in patients, and the correlation of diabetes with hepatic dysfunctions. It also includes papers related to the immunological aspects in the journey to prevent and reverse the disease.

With more interaction and collaborations, we can bring an end to T1DM and give a better life to the children who are at risk to develop this immensely agonising disease.

2 Patents

Diabetec foot ulcer (DFU) treatment using stem cell, Wound healing

26 Publications

T1DM vaccine research, Regenerative medicine research, 15 under process

10 Awards

'Woman Innovator' National Award 2022 and others, for research in T1DM

Journey So Far

2016

July

Inception of Idea

Development of vaccine to prevent and reverse type 1 diabetes mellitus

2018

September

t1dm.org Launched

Platform launched to consolidate research work about type 1 diabetes and its management

t1dm.org invites an open interaction from national and international experts to manage type 1 diabetes, share their knowledge and collaborate to work towards freedom from this painful disease

2020

June

Research Publication

First review paper on type 1 diabetes mellitus “Mapping of type 1 diabetes mellitus” published in Current Diabetes Reviews

2021

December

Preclinical Model Development

Preclinical model development project using Swiss albino mice started to study type 1 diabetes

2022

April

Phase 1 Preclinical Study

Stability test for vaccine formula conducted
Allergy test and safety study for vaccine formula conducted
Efficacy study of vaccine formula to prevent and reverse type 1 diabetes mellitus

My Latest Publications

Showing posts with label children. Show all posts
Showing posts with label children. Show all posts

Trigger For T1DM: A Research Map


Scientists have identified the possible trigger for type 1 diabetes mellitus (T1DM).

The T cells of the immune system do not recognise self-antigens, i.e., the body’s own cells. Therefore, they are protected from the attack of the immune system. In T1DM and other autoimmune disorders, this protective system gets disrupted1.

Dr Delong and his colleagues carried out an experiment to study the trigger in T1DM. They isolated T cells from a T1DM mouse model and determined the trigger that is recognised as a foreign body in the insulin-producing β-cells. They recognised a modified version of insulin which acted as an antigen. They also observed that the immune T cells from pancreatic islets of two organ donors with T1DM recognised hybrid insulin peptides (HIPs). This study concluded that these HIPs may have a significant role as a trigger to the immune system and hence attack the body’s insulin-producing pancreatic β-cells, thus causing T1DM1. Antibodies from the blood of T1DM patients recognised the HIPs in the mouse. This suggests that a human equivalent may also exist.

Insulin is considered to be an important autoantigen for β-cell in T1DM. However, according to a recent discovery, two more secretory granule proteins, islet amyloid polypeptide (IAPP) and chromogranin A (Chg A), are also considered to be the source of antigenic peptides in T1DM2.

Conclusion

HIPs act as key antigens for the autoreactive T cells and causes loss of self-tolerance in human T1DM. They may also form in the other endocrine tissues and could be a trigger for self-antigens in other autoimmune disorders.

References
  1. Delong T, et al. Pathogenic CD4T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science. 2017;351(6274): 676-678.
  2. Haskins, Kathryn M. Hybrid Peptides as Autoantigens for Diabetogenic CD4T Cells. National Institutes of Health. (http://grantome.com/grant/NIH/R01-DK081166-06A1).

Type 1 Diabetes Mellitus: Aetiology And Pathogenesis

T1DM is allied with the selective destruction of insulin-producing β-cells in the pancreas. The commencement of clinical disease signifies the end stage of β-cell destruction which leads to T1DM. There is marked heterogeneity of the pancreatic lesions, which makes it difficult to follow the pathogenesis of selective β-cell destruction within the islet in T1DM1.


Type 1 Diabetes Mellitus: An Alarming Condition

Diabetes mellitus (DM), a metabolic disorder, is mainly of two types. Type 1 Diabetes Mellitus (T1DM), insulin dependent DM, is an autoimmune reaction to proteins of the islet cells of the pancreas. There is a lack of insulin secretion by β- cells of the pancreas. Type 2 Diabetes Mellitus (T2DM), non-insulin dependent DM, is a combination of genetic factors related to impaired insulin secretion, insulin resistance and environmental factors such as obesity, overeating, lack of exercise, stress, ageing. There is a decreased sensitivity of target tissues to insulin1.

Testimonials

Collaborate With Me

Contact Us

SHIVANI DESAI
+91-20-4930-0148
Pune, India